Brief: Auven therapeutics and Bellus Health announce completion of pivotal Phase 3 confirmatory trial of KIACTA for the treatment of orphan disease
21/01/2016 13:00
Jan 21 (Reuters) - BELLUS Health Inc BLU.TO : * Auven Therapeutics and Bellus Health announce completion of pivotal Phase 3 confirmatory trial of KIACTA for the treatment of orphan disease AA amyloidosis * Top-line results are expected to be announced in Q2 2016 after all remaining patients have completed final study visits * Source text for Eikon urn:newsml:reuters.com:*:nGNXMKXKGa * Further company coverage BLU.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln